Event

Sabrina Wiebe

MSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Sophie Fletcher

BM Bch
Southampton University Hospitals NHS Trust;University Hospital Southampton and Southampton NIHR Respiratory Biomedical Research Unit, Universit

Nazia Chaudhuri

MBChB
North West Lung Centre, Manchester University NHS Foundation Trust;Univ of Sheffield

Huzaifa Adamali

M.D.
North Bristol NHS Trust, Southmead Hospital

Kathrin Hohl

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Toby M. Maher

MD, MSc, PhD, FRCP
Imperial College;Imperial College London;Imperial College, London;National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Hare;Royal Brompton and Harefield NHS

Luca Richeldi

MD, PhD
Catholic University of the Sacred Heart;Clinical and Experimental Sciences, University of Southampton;Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli;University of Southampton

Andrew Baker

MSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Sven Wind

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Rozsa Schlenker-Herceg

M.D.
Boehringer Ingelheim Pharmaceuticals, Inc.

Susanne Stowasser

M.D.
Boehringer Ingelheim Pharma GmbH & Co. KG

No Relevant Pharmacokinetic Interaction Between Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF): Results from a Drug-Drug Interaction Study